Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

225 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer.
Veeraraghavan J, Gutierrez C, De Angelis C, Davis R, Wang T, Pascual T, Selenica P, Sanchez K, Nitta H, Kapadia M, Pavlick AC, Galvan P, Rexer B, Forero-Torres A, Nanda R, Storniolo AM, Krop IE, Goetz MP, Nangia JR, Wolff AC, Weigelt B, Reis-Filho JS, Hilsenbeck SG, Prat A, Osborne CK, Schiff R, Rimawi MF. Veeraraghavan J, et al. Among authors: krop ie. Clin Cancer Res. 2023 Aug 15;29(16):3101-3109. doi: 10.1158/1078-0432.CCR-22-3753. Clin Cancer Res. 2023. PMID: 37195235 Free PMC article.
A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.
Krop IE, LoRusso P, Miller KD, Modi S, Yardley D, Rodriguez G, Guardino E, Lu M, Zheng M, Girish S, Amler L, Winer EP, Rugo HS. Krop IE, et al. J Clin Oncol. 2012 Sep 10;30(26):3234-41. doi: 10.1200/JCO.2011.40.5902. Epub 2012 May 29. J Clin Oncol. 2012. PMID: 22649126 Clinical Trial.
Prevalence of germline TP53 mutations in HER2+ breast cancer patients.
Rath MG, Masciari S, Gelman R, Miron A, Miron P, Foley K, Richardson AL, Krop IE, Verselis SJ, Dillon DA, Garber JE. Rath MG, et al. Among authors: krop ie. Breast Cancer Res Treat. 2013 May;139(1):193-8. doi: 10.1007/s10549-012-2375-z. Epub 2013 Apr 12. Breast Cancer Res Treat. 2013. PMID: 23580068 Free PMC article.
Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort study.
Vaz-Luis I, Seah D, Olson EM, Wagle N, Metzger-Filho O, Sohl J, Litsas G, Burstein HJ, Krop IE, Winer EP, Lin NU. Vaz-Luis I, et al. Among authors: krop ie. Clin Breast Cancer. 2013 Aug;13(4):254-63. doi: 10.1016/j.clbc.2013.02.010. Clin Breast Cancer. 2013. PMID: 23829891 Free PMC article.
Pertuzumab: optimizing HER2 blockade.
Metzger-Filho O, Winer EP, Krop I. Metzger-Filho O, et al. Clin Cancer Res. 2013 Oct 15;19(20):5552-6. doi: 10.1158/1078-0432.CCR-13-0518. Epub 2013 Aug 13. Clin Cancer Res. 2013. PMID: 23942091 Review.
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.
Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis M, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Partridge AH, Guo H, Hudis CA, Krop IE, Burstein HJ, Winer EP. Tolaney SM, et al. Among authors: krop ie. N Engl J Med. 2015 Jan 8;372(2):134-41. doi: 10.1056/NEJMoa1406281. N Engl J Med. 2015. PMID: 25564897 Free PMC article. Clinical Trial.
Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial).
Ruddy KJ, Guo H, Barry W, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis MJ, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Hudis C, Krop IE, Burstein HJ, Winer EP, Partridge AH, Tolaney SM. Ruddy KJ, et al. Among authors: krop ie. Breast Cancer Res Treat. 2015 Jun;151(3):589-96. doi: 10.1007/s10549-015-3426-z. Epub 2015 May 16. Breast Cancer Res Treat. 2015. PMID: 25981899 Free PMC article.
Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003).
Lin NU, Guo H, Yap JT, Mayer IA, Falkson CI, Hobday TJ, Dees EC, Richardson AL, Nanda R, Rimawi MF, Ryabin N, Najita JS, Barry WT, Arteaga CL, Wolff AC, Krop IE, Winer EP, Van den Abbeele AD. Lin NU, et al. Among authors: krop ie. J Clin Oncol. 2015 Aug 20;33(24):2623-31. doi: 10.1200/JCO.2014.60.0353. Epub 2015 Jul 13. J Clin Oncol. 2015. PMID: 26169615 Free PMC article. Clinical Trial.
Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.
Carey LA, Berry DA, Cirrincione CT, Barry WT, Pitcher BN, Harris LN, Ollila DW, Krop IE, Henry NL, Weckstein DJ, Anders CK, Singh B, Hoadley KA, Iglesia M, Cheang MC, Perou CM, Winer EP, Hudis CA. Carey LA, et al. Among authors: krop ie. J Clin Oncol. 2016 Feb 20;34(6):542-9. doi: 10.1200/JCO.2015.62.1268. Epub 2015 Nov 2. J Clin Oncol. 2016. PMID: 26527775 Free PMC article. Clinical Trial.
225 results